Experimental vaccine trains immune system to fight Hard-to-Treat cancers
NCT ID NCT05631899
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a personalized vaccine made from a patient's own immune cells, designed to target specific cancer markers (EphA2 and KRAS mutations). The vaccine is given along with chemotherapy and two immunotherapy drugs. The study includes 9 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the vaccine can boost the immune system's ability to fight the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized dendritic cell vaccine (KRAS-EphA-2-CAR-DC) combined with chemotherapy and immune checkpoint inhibitors
What this could lead to
If successful, this approach could offer a new treatment option for people with advanced solid tumors that have specific genetic markers.
What could go wrong
This is a very early, small trial (9 participants) focused on safety. The treatment may not shrink tumors or improve survival, and side effects like cytokine release syndrome are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biotherapeutic Department of Chinsese PLA Gereral Hospital
Beijing, Beijing Municipality, 100853, China